FI944730A7 - CD33:lle sukua olevien pinta-antigeenien vastaisia immuunitoksiineja - Google Patents

CD33:lle sukua olevien pinta-antigeenien vastaisia immuunitoksiineja Download PDF

Info

Publication number
FI944730A7
FI944730A7 FI944730A FI944730A FI944730A7 FI 944730 A7 FI944730 A7 FI 944730A7 FI 944730 A FI944730 A FI 944730A FI 944730 A FI944730 A FI 944730A FI 944730 A7 FI944730 A7 FI 944730A7
Authority
FI
Finland
Prior art keywords
immunotoxins
surface antigens
against surface
treatment
present
Prior art date
Application number
FI944730A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI944730A0 (fi
FI944730L (fi
Inventor
Michael G Rosenblum
Original Assignee
Res Found Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Found Dev filed Critical Res Found Dev
Publication of FI944730A0 publication Critical patent/FI944730A0/fi
Publication of FI944730L publication Critical patent/FI944730L/fi
Publication of FI944730A7 publication Critical patent/FI944730A7/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI944730A 1992-04-10 1993-04-08 CD33:lle sukua olevien pinta-antigeenien vastaisia immuunitoksiineja FI944730A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86669392A 1992-04-10 1992-04-10
PCT/US1993/003284 WO1993020848A1 (en) 1992-04-10 1993-04-08 Immunotoxins directed against cd33 related surface antigens

Publications (3)

Publication Number Publication Date
FI944730A0 FI944730A0 (fi) 1994-10-07
FI944730L FI944730L (fi) 1994-10-07
FI944730A7 true FI944730A7 (fi) 1994-10-07

Family

ID=25348185

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944730A FI944730A7 (fi) 1992-04-10 1993-04-08 CD33:lle sukua olevien pinta-antigeenien vastaisia immuunitoksiineja

Country Status (13)

Country Link
EP (2) EP1656950A1 (enExample)
JP (1) JP3949158B2 (enExample)
KR (1) KR950700760A (enExample)
CN (1) CN1056084C (enExample)
AU (1) AU675226B2 (enExample)
CA (1) CA2133838C (enExample)
FI (1) FI944730A7 (enExample)
IL (1) IL105344A (enExample)
NO (1) NO314686B1 (enExample)
NZ (1) NZ252799A (enExample)
RU (1) RU2127122C1 (enExample)
WO (1) WO1993020848A1 (enExample)
ZA (1) ZA932523B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599505B1 (en) 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
CA2448123C (en) * 2001-05-24 2012-09-11 Zymogenetics, Inc. Taci-immunoglobulin fusion proteins
TW200726776A (en) * 2005-07-29 2007-07-16 Friedrich Alexander University Of Erlangen Nuremberg CD33-specific single-chain immunotoxin and methods of use
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
JP7376977B2 (ja) 2015-06-12 2023-11-09 アレクトル エルエルシー 抗cd33抗体及びその使用方法
AU2018310985A1 (en) 2017-08-03 2019-11-07 Alector Llc Anti-CD33 antibodies and methods of use thereof
BR112021003016A2 (pt) 2018-08-31 2021-05-18 Alector Llc anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um anticorpo e para prevenir, reduzir o risco ou tratar uma doença e composição farmacêutica
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
DE69033631T2 (de) * 1989-12-14 2001-05-17 Sloan-Kettering Institute For Cancer Research, New York Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon

Also Published As

Publication number Publication date
IL105344A (en) 2000-06-29
AU675226B2 (en) 1997-01-30
KR950700760A (ko) 1995-02-20
CN1078401A (zh) 1993-11-17
JP3949158B2 (ja) 2007-07-25
WO1993020848A1 (en) 1993-10-28
CA2133838A1 (en) 1993-10-28
AU4280193A (en) 1993-11-18
RU2127122C1 (ru) 1999-03-10
ZA932523B (en) 1994-10-08
EP0634938A1 (en) 1995-01-25
IL105344A0 (en) 1993-08-18
NO943776L (no) 1994-11-25
NO943776D0 (no) 1994-10-07
FI944730A0 (fi) 1994-10-07
FI944730L (fi) 1994-10-07
CA2133838C (en) 2003-07-29
NZ252799A (en) 1996-10-28
NO314686B1 (no) 2003-05-05
KR100291377B1 (enExample) 2001-09-17
EP1656950A1 (en) 2006-05-17
EP0634938A4 (en) 1998-06-03
JPH08501059A (ja) 1996-02-06
CN1056084C (zh) 2000-09-06

Similar Documents

Publication Publication Date Title
FI944730A7 (fi) CD33:lle sukua olevien pinta-antigeenien vastaisia immuunitoksiineja
EP0635030A4 (en) AGAINST C-ERB B-2 (HER-2 / -1 (NEW)) RELATED IMMUNO TOXINS.
NO166943C (no) Analogifremgangsmaate for fremstilling av enzymresistente immunomodulerende peptider.
SE8000435L (sv) N-bensylimidazoler med selektivt inhiberande verkan pa tromboxansyntetasenzymet jemte farmaceutiska beredningar innehallande sadana n-bensylimidazoler och sett for deras framstellning
NO852093L (no) Humane monoclonale antistoffer mot serotypiske lipopolysakkarid-determinanter paa gram-negative bakterier og fremstilling derav.
DE69813839D1 (de) Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz
SE8605295D0 (sv) Monoclonal antibodies cross-reactive and crossprotective against p. aeruginosa serotypes
NO932101D0 (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
IL124015A0 (en) Pharmaceutical compositions comprising a protein
DE69940980D1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
Kumta et al. Radiation damage to proteins
IT8319385A0 (it) Prodotti di cioccolato con maggiore contenuto di proteine eprocedimento per la produzione diprodotti di tipo siffatto.
ES2079068T3 (es) 2-amino-6-fenil-4h-piran-4-onas antiateroscleroticas y antitromboticas.
BG101038A (bg) Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък
DK0841912T3 (da) 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
SE7606971L (sv) Adriamycinestrar
RU94045984A (ru) Композиция, способ обработки неопластической клетки, способ уничтожения опухолевых клеток
DE60133104D1 (de) Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren
DK0579791T3 (da) Cellulær sammensætning til behandling af menneske- og dyreorganismer
EP0120835A3 (en) Process for the inactivation of incompatibility inducing substances
DE69232140D1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
LU79238A1 (fr) Procede de preparation de compositions biologiquement actives contre la formation de lipides et de cholesterol chez les mammiferes
LU81273A1 (fr) Proteine purifiee associee au cancer
IT7828549A0 (it) Composizione terapeutica per il trattamento di infezioni e malattie di animali da allevamento.

Legal Events

Date Code Title Description
FD Application lapsed